PDCD1 and neoplasm: However, αTIGIT + bintrafusp alfa Responders had the highest frequency of dual-positive CD8+ T cells co-expressing PD-1 and LAG3 per mg of tumor in comparison to all other treatment groups (p < .0001; Figure 4e).